• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Pharma Pulse 5/21/24: Musk’s Neuralink Gets FDA Green Light for Second Patient, Uber Caregiver to Support Caregivers Across the US & more


The latest news for pharma industry insiders.

What’s Complicating Good Data Practices and Data Integrity?

Companies must be able to defend the fidelity and confidentiality of all records and data generated throughout a product’s entire lifecycle, starting with the earliest points in research.

Uber Health’s New App, Uber Caregiver to Support Caregivers Across the US

Set to launch this summer, Uber Caregiver is tailored specifically for caregivers and their loved ones, aiming to tackle challenges head on and enhance the overall care experience.

Elon Musk’s Neuralink Gets FDA Green Light for Second Patient, as First Describes His Emotional Journey

Brain-chip startup has proposed solutions for thread pullout problem experienced by first participant, Noland Arbaugh

Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers

Hims & Hers unlocks access to injectable GLP-1 medications, expanding its holistic weight loss program focused on personalized and affordable solutions; prices start as low as $199 a month

Challenger, Gray & Christmas, Inc. on LinkedIn:

AI in the workplace with #ChallengerReport data in a Pharmaceutical Executive Magazine Q&A with Frances Frei by emeritus board member of the Harvard Business School HBS Healthcare Alumni Association, Michael Wong.

When the topic of artificial intelligence (AI) and its potential impact on jobs comes up, an often-cited platitude is that while some jobs will be eliminated, new ones will be created. Still, the reality is that as Challenger, Gray, and Christmas recently reported, “In light of the backlash some companies have faced for directly attributing job cuts to artificial intelligence, they appear to be framing this shift as a ‘technological update’ rather than an outright substitution of human roles with AI. In truth, companies are also implementing robotics and automation in addition to AI.

See Frei's answer:https://bit.ly/3K7nEqM

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs